Login to Your Account

Windmil tilts at tumors with marrow-infiltrating lymphocytes

By Michael Fitzhugh
Staff Writer

Friday, October 6, 2017

Windmil Therapeutics Inc., a startup harnessing the power of bone marrow-infiltrating lymphocytes, or MILs, for cancer immunotherapy, has nearly completed enrollment of patients in a phase IIb trial testing its approach in high-risk myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription